SLC34A2 as a novel marker for diagnosis and targeted therapy of breast cancer

Dar Ren Chen, Su Yu Chien, Shou Jen Kuo, Ying Hock Teng, Hsiu Ting Tsai, Jehn Hwa Kuo, Jing Gung Chung

Research output: Contribution to journalArticle

24 Citations (Scopus)

Abstract

The purpose of this study was to estimate the role of the SLC34A2 gene in breast cancer. A total of 146 samples were collected from breast cancer tissues and their adjacent normal breast tissues. Reverse transcription and real-time polymerase chain reaction were used to estimate gene expression levels. There was a significantly increased gene expression of SLC34A2 (normal tissues: 6.71±0.77; tumour tissues: 10.29±0.80) among breast cancer tissues compared with normal tissues. However, there was no significant association between overall survival and the gene expression level of SLC34A2. Moreover, a significant overexpression of CA125 (normal tissues: 7.26±0.62; tumour tissues: 10.51±0.58) in breast cancer tissues and a significant correlation between SLC34A2 and CA125 gene expressions were found. Our results suggested SLC34A2 to be involved in the development of breast cancer; this gene may therefore be a novel marker for the detection of breast cancer and act as a target gene in therapeutic strategies.

Original languageEnglish
Pages (from-to)4135-4140
Number of pages6
JournalAnticancer Research
Volume30
Issue number10
Publication statusPublished - Oct 2010
Externally publishedYes

Fingerprint

Breast Neoplasms
Gene Expression
Therapeutics
Genes
Reverse Transcription
Real-Time Polymerase Chain Reaction
Neoplasms
Breast

Keywords

  • Breast cancer
  • Diagnosis
  • SLC34A2
  • Therapy
  • Type II sodium-dependent phosphate transporter

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Chen, D. R., Chien, S. Y., Kuo, S. J., Teng, Y. H., Tsai, H. T., Kuo, J. H., & Chung, J. G. (2010). SLC34A2 as a novel marker for diagnosis and targeted therapy of breast cancer. Anticancer Research, 30(10), 4135-4140.

SLC34A2 as a novel marker for diagnosis and targeted therapy of breast cancer. / Chen, Dar Ren; Chien, Su Yu; Kuo, Shou Jen; Teng, Ying Hock; Tsai, Hsiu Ting; Kuo, Jehn Hwa; Chung, Jing Gung.

In: Anticancer Research, Vol. 30, No. 10, 10.2010, p. 4135-4140.

Research output: Contribution to journalArticle

Chen, DR, Chien, SY, Kuo, SJ, Teng, YH, Tsai, HT, Kuo, JH & Chung, JG 2010, 'SLC34A2 as a novel marker for diagnosis and targeted therapy of breast cancer', Anticancer Research, vol. 30, no. 10, pp. 4135-4140.
Chen DR, Chien SY, Kuo SJ, Teng YH, Tsai HT, Kuo JH et al. SLC34A2 as a novel marker for diagnosis and targeted therapy of breast cancer. Anticancer Research. 2010 Oct;30(10):4135-4140.
Chen, Dar Ren ; Chien, Su Yu ; Kuo, Shou Jen ; Teng, Ying Hock ; Tsai, Hsiu Ting ; Kuo, Jehn Hwa ; Chung, Jing Gung. / SLC34A2 as a novel marker for diagnosis and targeted therapy of breast cancer. In: Anticancer Research. 2010 ; Vol. 30, No. 10. pp. 4135-4140.
@article{2f332b618f104e12a9ac327c29acadc2,
title = "SLC34A2 as a novel marker for diagnosis and targeted therapy of breast cancer",
abstract = "The purpose of this study was to estimate the role of the SLC34A2 gene in breast cancer. A total of 146 samples were collected from breast cancer tissues and their adjacent normal breast tissues. Reverse transcription and real-time polymerase chain reaction were used to estimate gene expression levels. There was a significantly increased gene expression of SLC34A2 (normal tissues: 6.71±0.77; tumour tissues: 10.29±0.80) among breast cancer tissues compared with normal tissues. However, there was no significant association between overall survival and the gene expression level of SLC34A2. Moreover, a significant overexpression of CA125 (normal tissues: 7.26±0.62; tumour tissues: 10.51±0.58) in breast cancer tissues and a significant correlation between SLC34A2 and CA125 gene expressions were found. Our results suggested SLC34A2 to be involved in the development of breast cancer; this gene may therefore be a novel marker for the detection of breast cancer and act as a target gene in therapeutic strategies.",
keywords = "Breast cancer, Diagnosis, SLC34A2, Therapy, Type II sodium-dependent phosphate transporter",
author = "Chen, {Dar Ren} and Chien, {Su Yu} and Kuo, {Shou Jen} and Teng, {Ying Hock} and Tsai, {Hsiu Ting} and Kuo, {Jehn Hwa} and Chung, {Jing Gung}",
year = "2010",
month = "10",
language = "English",
volume = "30",
pages = "4135--4140",
journal = "Anticancer Research",
issn = "0250-7005",
publisher = "International Institute of Anticancer Research",
number = "10",

}

TY - JOUR

T1 - SLC34A2 as a novel marker for diagnosis and targeted therapy of breast cancer

AU - Chen, Dar Ren

AU - Chien, Su Yu

AU - Kuo, Shou Jen

AU - Teng, Ying Hock

AU - Tsai, Hsiu Ting

AU - Kuo, Jehn Hwa

AU - Chung, Jing Gung

PY - 2010/10

Y1 - 2010/10

N2 - The purpose of this study was to estimate the role of the SLC34A2 gene in breast cancer. A total of 146 samples were collected from breast cancer tissues and their adjacent normal breast tissues. Reverse transcription and real-time polymerase chain reaction were used to estimate gene expression levels. There was a significantly increased gene expression of SLC34A2 (normal tissues: 6.71±0.77; tumour tissues: 10.29±0.80) among breast cancer tissues compared with normal tissues. However, there was no significant association between overall survival and the gene expression level of SLC34A2. Moreover, a significant overexpression of CA125 (normal tissues: 7.26±0.62; tumour tissues: 10.51±0.58) in breast cancer tissues and a significant correlation between SLC34A2 and CA125 gene expressions were found. Our results suggested SLC34A2 to be involved in the development of breast cancer; this gene may therefore be a novel marker for the detection of breast cancer and act as a target gene in therapeutic strategies.

AB - The purpose of this study was to estimate the role of the SLC34A2 gene in breast cancer. A total of 146 samples were collected from breast cancer tissues and their adjacent normal breast tissues. Reverse transcription and real-time polymerase chain reaction were used to estimate gene expression levels. There was a significantly increased gene expression of SLC34A2 (normal tissues: 6.71±0.77; tumour tissues: 10.29±0.80) among breast cancer tissues compared with normal tissues. However, there was no significant association between overall survival and the gene expression level of SLC34A2. Moreover, a significant overexpression of CA125 (normal tissues: 7.26±0.62; tumour tissues: 10.51±0.58) in breast cancer tissues and a significant correlation between SLC34A2 and CA125 gene expressions were found. Our results suggested SLC34A2 to be involved in the development of breast cancer; this gene may therefore be a novel marker for the detection of breast cancer and act as a target gene in therapeutic strategies.

KW - Breast cancer

KW - Diagnosis

KW - SLC34A2

KW - Therapy

KW - Type II sodium-dependent phosphate transporter

UR - http://www.scopus.com/inward/record.url?scp=78650254275&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=78650254275&partnerID=8YFLogxK

M3 - Article

VL - 30

SP - 4135

EP - 4140

JO - Anticancer Research

JF - Anticancer Research

SN - 0250-7005

IS - 10

ER -